Dexlansoprazole

Mechanism :

Proton pump inhibitor; decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system.

Indication :

GERD
Erosive esophagitis

Contraindications :

Known hypersensitivity to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.

Dosing :

≥12 years of age.

GERD:

30 mg once daily for 4 weeks orally.

Erosive esophagitis:

Healing: 60 mg once daily for up to 8 weeks, Maintenance: 30 mg orally once daily for upto 16 weeks.

Adverse Effect :

Abdominal pain, diarrhea, flatulence, abdominal distress and tenderness, Barrett esophagus, angina pectoris, bradycardia, arrhythmias, chest pain, DVT, hypertension, headache, dizziness, falling, psychomotor agitation, anemia, thrombocytopenia, abnormal hepatic functions tests.

Interaction :

Clopidogrel: Dexlansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.
Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.
Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.
Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.
Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole.

Hepatic Dose :

Mild hepatic impairment: No dose adjustment required.
Moderate hepatic impairment: Do not use more than 30 mg PO daily.
Severe hepatic impairment: Avoid use.